Home » Stocks » BNR

Burning Rock Biotech Ltd. (BNR)

Stock Price: $29.56 USD -1.04 (-3.40%)
Updated Apr 16, 2021 4:00 PM EDT - Market closed
Market Cap 3.09B
Revenue (ttm) 65.73M
Net Income (ttm) -72.16M
Shares Out 104.55M
EPS (ttm) -1.05
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 16
Last Price $29.56
Previous Close $30.60
Change ($) -1.04
Change (%) -3.40%
Day's Open 30.50
Day's Range 28.28 - 30.44
Day's Volume 126,061
52-Week Range 18.64 - 39.75

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

GUANGZHOU, China, April 13, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that its liquid biopsy assay has achieved strong performa...

5 days ago - GlobeNewsWire

GUANGZHOU, China, March 10, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS)...

1 month ago - GlobeNewsWire

GUANGZHOU, China, Feb. 08, 2021 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”), a company focused on the application of next generation sequencing (NGS) ...

2 months ago - GlobeNewsWire

Burning Rock (BNR) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

2 months ago - Zacks Investment Research

Burning Rock Biotech went public in the U.S. in June 2020. The firm provides a range of early detection and therapy selection testing services in China.

3 months ago - Seeking Alpha

Shares of OncoCyte Corp. rocketed 63% on very heavy volume in premarket trading Tuesday, after the molecular diagnostics company announced overnight that it entered into an exclusive licensing agreement...

Other stocks mentioned: OCX
4 months ago - Market Watch

About BNR

Burning Rock Biotech Limited primarily develops and provides cancer therapy selection tests in the People's Republic of China. The company primarily offers 12 next-generation sequencing-based cancer therapy selection tests applicable to a range of cancer types, including lung cancer, gastrointestinal cancer, prostate cancer, breast cancer, lymphomas, thyroid cancer, colorectal cancer, ovarian cancer, pancreatic cancer, and bladder cancer using tissue and liquid biopsy samples. Its principal products include OncoScreen IO, a pan-cancer test for ... [Read more...]

Industry
Diagnostics & Research
IPO Date
Jun 12, 2020
Stock Exchange
NASDAQ
Ticker Symbol
BNR
Full Company Profile

Financial Performance

In 2020, BNR's revenue was 429.90 million, an increase of 12.64% compared to the previous year's 381.68 million. Losses were -407.24 million, 140.7% more than in 2019.

Financial numbers in millions CNY.
Financial Statements

Analyst Forecasts

According to 3 analysts, the average rating for BNR stock is "Strong Buy." The 12-month stock price forecast is 23.18, which is a decrease of -21.58% from the latest price.

Price Target
$23.18
(-21.58% downside)
Analyst Consensus: Strong Buy